Non-small cell lung cancer - cachexia (nsclc-c)
Drug research and approvals for non-small cell lung cancer - cachexia (nsclc-c): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 0 studies of non-small cell lung cancer - cachexia (nsclc-c) are recruiting on ClinicalTrials.gov, and Health Canada has authorized 6 drug trials for it since 2013.
- Recruiting worldwide: 0
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
Trials Authorized in Canada
Newest first; search them all in Canada trials| Jun 25, 2026 | An interventional, phase 1 b, double-blind, randomized, sponsor-open, 2-arm study to investigate the effect of ponsegromab on skeletal muscle mass and physical…PONSEGROMAB (PF-06946860) | Pfizer | Pending |
| Feb 11, 2026 | Rosetta lung-201: a randomized, multicenter, open-label phase 3 study of pumitamig monotherapy compared to durvalumab in participants with unresectable stage…PUMITAMIG (BMS-986545; BNT327) | Bristol-Myers Squibb | Ongoing |
| Oct 10, 2025 | A phase 2b/3, randomized, double-blind study to investigate the efficacy, safety, and tolerability of ponsegromab (pf-06946860) compared with placebo both with…PONSEGROMAB (PF-06946860) | Pfizer | Ongoing |
| Feb 28, 2024 | A phase 3 randomized open-label study of adjuvant pembrolizumab with or without mk-2870 in participants with resectable stage ii to iiib (n2) nsclc not…MK-2870 (SKB264) / KEYTRUDA | Merck & Co. (MSD) | Ongoing |
| Nov 3, 2022 | A phase III, randomised, open-label, multicentre, global study of datopotamab deruxtecan (dato-dxd) in combination with durvalumab and carboplatin versus…IMFINZI / DATOPOTAMAB DERUXTECAN (DATO-DXD; DS-1062A) | AstraZeneca Pharmaceuticals LP | Ongoing |
| Aug 31, 2022 | A phase 2a randomized, double-blind, placebo controlled multicenter study to investigate the efficacy, safety, tolerability, pharmacokinetics and…PONSEGROMAB (PF-06946860) | Pfizer | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA